Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination therapy for children with malignant pontine gliomas
NL-OMON28201Phase 2Recruiting
- Sponsor
- VU University Medical Center
- Start
- Mar 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine, irinotecan, bevacizumab, erlotinib and everolimus in diffuse intrinsic pontine glioma (DIPG) (4 arms), sponsored by VU University Medical Center. Primary endpoints: Tolerability of gemcitabine, Tolerability of erlotinib and everolimus added to bevacizumab-irinotecan and 1 more. Started Mar 2011; status: recruiting.
02
Drugs
gemcitabineirinotecanbevacizumaberlotinibeverolimus
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NL-OMON28201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28201.